Amgen’s Mvasi Biosimilar Overtakes Avastin In The US
California-Based Giant Enjoyed Biosimilars Sales Of $1.7bn Last Year
Amgen enters 2021 with a five-strong global biosimilars portfolio, spearheaded by its market-leading bevacizumab and trastuzumab products in the US. Management explained the contrasting fates of the two oncology biosimilars as it published full-year financial results.
